If you take Elmiron and have noticed wavy lines or blurred central vision, these could be early signs of pigmentary maculopathy. Building on years of pharmacovigilance data, this page explains when retinal changes typically begin, what symptoms to watch for, and how eye specialists recommend monitoring your vision.
Elmiron (pentosan polysulfate sodium) is a medication approved for the treatment of interstitial cystitis, a chronic bladder condition. Long-term use of Elmiron has been associated with the development of pigmentary maculopathy, a retinal condition that can cause visual symptoms. The U.S. Food and Drug Administration (FDA) label for Elmiron includes a warning about retinal pigmentary changes, noting that these changes have been identified with long-term use, with most cases occurring after three years or more, though cases have been seen with shorter durations of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The label states that cumulative dose appears to be a risk factor, and the visual consequences of these pigmentary changes are not fully characterized (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Clinical presentation of pigmentary maculopathy in Elmiron users typically includes difficulty reading, slow adjustment to low or reduced light environments, and blurred vision (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Diagnosis relies on ophthalmologic examination, including color fundoscopic photography, ocular coherence tomography (OCT), and auto-fluorescence imaging (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The FDA label recommends obtaining a detailed ophthalmologic history before starting treatment, and for patients with pre-existing ophthalmologic conditions, a comprehensive baseline retinal examination is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). For all patients, a baseline retinal examination including OCT and auto-fluorescence imaging is suggested within six months of initiating treatment and periodically thereafter (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). If pigmentary changes develop, the risks and benefits of continuing treatment should be re-evaluated, as these changes may be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The mechanistic pathways linking Elmiron to pigmentary maculopathy are not fully established, but the FDA label notes that the etiology is unclear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
Research has examined the association between pentosan polysulfate exposure and pigmentary maculopathy in patients with interstitial cystitis. A single-center retrospective study at Wake Forest School of Medicine evaluated patients with interstitial cystitis who had at least two eye examinations between January 2011 and August 2021 (https://pubmed.ncbi.nlm.nih.gov/41049115/). The study used masked retina specialists to evaluate multimodal imaging for pigmentary maculopathy, with cases categorized by severity and analyzed for associations with medication exposure, including exposure duration and cumulative dose (https://pubmed.ncbi.nlm.nih.gov/41049115/). Adverse event reports from the FDA Adverse Event Reporting System (FAERS) provide additional data on the frequency of reported events associated with Elmiron. The most frequently reported adverse events include maculopathy (1382 reports), off-label use (1361 reports), retinal pigmentation (607 reports), dry age-related macular degeneration (560 reports), and pigmentary maculopathy (442 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). Other commonly reported events include visual impairment (150 reports), retinal dystrophy (141 reports), and neovascular age-related macular degeneration (141 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). These reports highlight the range of visual and retinal issues associated with Elmiron use.
Risk considerations for affected patients include the adequacy of warnings regarding Elmiron and pigmentary maculopathy. The FDA label includes a warning about retinal pigmentary changes, but patients may not have been fully informed of the risk before starting treatment. The label recommends baseline and periodic retinal examinations, but adherence to these recommendations may vary. For patients who develop pigmentary maculopathy, the timeline between exposure and documented harm is important. The label notes that most cases occur after three years or more of use, but cases have been seen with shorter durations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Cumulative dose is a risk factor, meaning that higher total exposure increases the likelihood of retinal changes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Attorney-related considerations for affected patients involve evaluating whether the manufacturer provided adequate warnings about the risk of pigmentary maculopathy. Patients who developed visual symptoms after long-term Elmiron use may seek legal counsel to explore potential claims. Settlement criteria in Elmiron pigmentary maculopathy lawsuits typically consider factors such as the duration and cumulative dose of Elmiron use, the severity of retinal changes and visual impairment, and whether the patient received appropriate monitoring and warnings. The FDA label's warning about retinal pigmentary changes and the recommendation for baseline and periodic eye exams may be relevant in assessing whether the manufacturer met its duty to warn. Additionally, the FAERS data showing a high number of maculopathy reports (1382) and pigmentary maculopathy reports (442) may support claims that the risk was known but not adequately communicated (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON).
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Elmiron (pentosan polysulfate sodium) is a medication for interstitial cystitis. Long-term use has been associated with pigmentary maculopathy, a retinal condition causing visual symptoms like difficulty reading and blurred vision. The FDA label includes a warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
Settlement criteria typically include duration and cumulative dose of Elmiron use, severity of retinal changes and visual impairment, and whether the patient received adequate warnings and monitoring. The FDA label's warning and FAERS data (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON) may be used to assess manufacturer liability.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.